5 results about "Rheumatologic Disorder" patented technology

The invention belongs to the technical field of medical instruments, and discloses an artificial intelligence-based rheumatism image auxiliary diagnosis device, which comprises a developing box and a base, a stretching structure is arranged in the developing box, and a lifting device is arranged at the bottom of the developing box. Through meshing transmission of the gear and the tooth groove and sliding fit of the T-shaped strip and the T-shaped groove, stable movement of the extension box is achieved, and the light guide piece can be flexibly unfolded and folded to adjust the display area; the reset spring assists in rolling the light guide sheet, and operation is efficient and convenient; the magnifying lens can adjust the horizontal position along the sliding groove through the sliding block, the angle is adjusted in combination with the universal support with damping, medical staff can conveniently and accurately observe details of rheumatism images, and the accuracy of auxiliary diagnosis is improved. And through cooperation of the rotating cylinder, the threaded rod and the telescopic rod, the height of the device is flexibly adjusted, the device can adapt to users of different heights, the operation comfort is improved, and actual application and operation are facilitated.

This invention discloses a method for predicting the efficacy of rheumatoid arthritis treatment based on multimodal feature fusion, relating to the fields of artificial intelligence and medical information processing. This method, targeting rheumatoid arthritis patients, integrates ultrasound images, radiomics features, and clinical characteristics to predict the efficacy response of traditional slow-acting antirheumatic drugs (csDMARDs). Specifically, it includes: standardizing and enhancing ultrasound images; extracting image depth features using a pre-trained ResNet convolutional neural network as the backbone model; extracting and standardizing radiomics and clinical features, and fusing them with image depth features through a Cross-Attention mechanism; optimizing feature distribution using supervised contrastive learning (SupConLoss) to improve model discriminative ability; and finally outputting the treatment response category through a fully connected layer. This invention establishes a high-performance predictive model with promising clinical applications by integrating ultrasound images, radiomics, and clinical data.

Rheumatoid arthritis (RA) is the most common form of inflammatory rheumatism involving small joints which are the seat for swelling and pain with structural damage, responsible for functional disabilities if no treatment is proposed. The inventors show that circulating MAIT cells were reduced and exhibited an activated and anti-apoptotic phenotype in RA patients compared to healthy controls. MAIT cell levels were also found to be increased in the synovial fluid as compared with the peripheral blood, suggesting that circulating MAIT cell deficiency is due to the migration of MAIT cells into the joint. Severity of arthritis induced by mBSA was reduced in mice depleted in MAIT cells. This data suggest that MAIT cells contribute to exacerbation of arthritis. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of rheumatoid arthritis

The invention discloses application of ubiquitination modification of protein in rheumatism related to cell inflammatory response and hypercoagulable state, and belongs to the technical field of rheumatism molecular biology. Ubiquitin-binding enzyme UBE2A is highly expressed in RA patients, and an NF-kappa B signal channel is activated by mediating ubiquitination modification of NEMO, so that inflammatory response and hypercoagulable state are promoted. Bioinformatics analysis, machine learning screening, a cell co-culture model and clinical sample verification are comprehensively utilized to prove that UBE2A is a key molecule in the RA pathogenesis process, and it is prompted that UBE2A can be used as a new target for RA diagnosis / treatment. Therefore, UBE2A and related pathways thereof can be used for preparing medicines for treating rheumatoid arthritis, especially for regulating inflammation and abnormal blood coagulation.